12830 EL CAMINO REAL, SAN DIEGO, CA
Acadia Pharmaceuticals Approves Amendment to 2024 Equity Incentive Plan
Earnings Release
Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Annual Report to Security Holders
Board Appointment - Jonathan M. Poole Joins Acadia Pharmaceuticals Board
Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals Anticipates Over $1 Billion in 2025 Net Sales
Reports Third Quarter 2025 Financial Results and Operating Overview
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
S-8 POS